Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2020’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)

– The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AB Science SA

AB2 Bio Ltd

Adamis Pharmaceuticals Corp

Afimmune Biopharma Ltd

Aibios Co Ltd

AlgiPharma AS

Allinaire Therapeutics LLC

Amgen Inc

Angiocrine Bioscience Inc

Apollo Therapeutics LLC

Aquilon Pharmaceuticals SA

Aridis Pharmaceuticals Inc

Ark Biosciences Inc

AstraZeneca Plc

AusBio Ltd

Avidin Ltd

Axolo Pharma Inc

Bai Shuo Beijing Pharmaceutical Technology Co Ltd

Bayer AG

BioMarck Pharmaceuticals Ltd

Boehringer Ingelheim International GmbH

C4X Discovery Holdings Plc

Cambryn Biologics LLC

Celon Pharma SA

Chiesi Farmaceutici SpA

China Resources Pharmaceutical Group Ltd

Cipla Ltd

Circassia Pharmaceuticals Plc

Covenant Therapeutics LLC

CSL Ltd

Cureveda LLC

Cytokinetics Inc

Daewoong Pharmaceutical Co Ltd

Denovo Biopharma LLC

Diffusion Pharmaceuticals Inc

Dimerix Ltd

Domainex Ltd

EmeraMed Ltd

EmphyCorp Inc

Emphymab Biotech LLC

Enzychem Lifesciences Corp

EpiEndo Pharmaceuticals Ehf

Epitracker Inc

Errant Gene Therapeutics LLC

ethris GmbH

Evaxion Biotech ApS

Exotect LLC

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals Co Ltd

Future Medicine Co Ltd

Galapagos NV

GeneFrontier Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Grifols SA

iCeutica Inc

Icure Pharmaceutical Inc

InMed Pharmaceuticals Inc

Inmunotek SL

Insmed Inc

Invion Ltd

Ionis Pharmaceuticals Inc

JiangSu Qyuns Therapeutics Co Ltd

Johnson & Johnson

KBP BioSciences Co Ltd

Kither Biotech Srl

Korea United Pharm Inc

Koutif Therapeutics LLC

Kyowa Kirin Co Ltd

LTT Bio-Pharma Co Ltd

Mariposa Health Ltd

MD Healthcare Inc

Mereo Biopharma Group Plc

Meridigen Biotech Co Ltd

Metagone Biotech Inc

MetrioPharm AG

Naegis Pharmaceuticals Inc

NB Health Laboratory Co Ltd

Novabiotics Ltd

Novartis AG

Omnispirant Ltd

OncoArendi Therapeutics SA

Oncostellae SL

Orchid Pharma Ltd

Orphomed Inc

Palo BioFarma SL

PharmaLundensis AB

Pharmaxis Ltd

Prous Institute for Biomedical Research SA

Pulmatrix Inc

Pulmotect Inc

Qu Biologics Inc

Quark Pharmaceuticals Inc

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Resolys Bio Inc

Respiratorius AB

Rhizen Pharmaceuticals SA

Santhera Pharmaceuticals Holding AG

Silurian Pharmaceuticals Inc

Silver Valley Pharmaceutical Co Ltd

SolAeroMed Inc

Sparrow Pharmaceuticals Inc

sterna biologicals Gmbh & Co KG

Sulfateq BV

Suzhou Connect Biopharmaceuticals Ltd

Symmune Therapeutics LLC

Synairgen Plc

Synovo GmbH

Syntrix Biosystems Inc

Taiho Pharmaceutical Co Ltd

Teva Pharmaceutical Industries Ltd

TFF Pharmaceuticals Inc

TGV-Inhalonix Inc

Theratrophix LLC

Torrent Pharmaceuticals Ltd

Unity Biotechnology Inc

Verona Pharma Plc

Verra Therapeutics LLC

Vicenna Pharmaceuticals Inc

vTv Therapeutics Inc

Yungjin Pharm Co Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Introduction

Chronic Obstructive Pulmonary Disease (COPD) - Overview

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by 3SBio Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AB Science SA, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AB2 Bio Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Adamis Pharmaceuticals Corp, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Afimmune Biopharma Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Aibios Co Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AlgiPharma AS, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Allinaire Therapeutics LLC, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Amgen Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angiocrine Bioscience Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports